UMIN ID: UMIN000001098
Registered date:26/03/2008
Randomized phase II study of docetaxel plus zoledronic acid versus docetaxel in patients with relapsing or refractory non-small cell lung cancer and bone metastasis
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | Non-small cell lung cancer |
| Date of first enrollment | 2007/05/01 |
| Target sample size | 100 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | Docetaxel plus zoledronic acid Docetaxel |
Outcome(s)
| Primary Outcome | Progression free survival |
|---|---|
| Secondary Outcome | Safety, Response rate, SRE rate, SRE free survival, Over all survival |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | Not applicable |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | >Previous treatment with docetaxel or zoledronic acid >Regular use of corticosteroidOral complication |
Related Information
| Primary Sponsor | West Japan Oncology Group |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | None |
| Secondary ID(s) |
Contact
| public contact | |
| Name | Shinichiro Nakamura |
| Address | Japan |
| Telephone | 06-6633-7400 |
| datacenter@wjog.jp | |
| Affiliation | West Japan Oncology Group WJOG datacenter |
| scientific contact | |
| Name | Haruyasu Murakami |
| Address | Shimonagakubo 1007, Nagaizumi-cho, Sunto-gun, Shizuoka, Japan Japan |
| Telephone | 055-989-5222 |
| Affiliation | Shizuoka Cancer Center Thoracic Oncology |